Safety
All-grade, TNBC, DLTs, arthralgias
ADVERSE EVENTS, ADVERSE EVENT
Adverse events are summarized in Table All-grade adverse events occurring in >2 patientsAll grade adverse events occurring in > 2 patients attributed as at least possibly related to either drug and stratified by dose level and grade (* denotes dose limiting toxicity).There were three DLTs on the trial, one in the 75 mcg/mTwo AEs of interest occurred during the trial. In the 50 mcg/mWe also looked at irAEs that would be normally associated with treatment with nivolumab; however, there were no grade ≥ 3 irAEs and no patients received steroids for management of any irAE. The only AE of any grade attributable as an irAE occurred in one patient. This was a patient with TNBC who experienced a complete response (CR) on trial and completed the 3 months of IFN-γ and the entire year of nivolumab. While on nivolumab alone, the patient experienced grade 2 arthralgias that started three months after completing IFN-γ. This was managed with anti-inflammatory supportive medications initially, later maintained on a tricyclic antidepressant.